Harm Reduction and Safety: What You Should Know Before Considering Psilocybin
An honest, evidence-based safety overview of psilocybin therapy — contraindications, common side effects, the importance of screening, and how clinical safety profiles compare to other common medications.
Any honest conversation about psilocybin therapy must include an equally honest conversation about safety. Psilocybin is remarkably safe in supervised clinical settings — but it is not without risks, it is not appropriate for everyone, and responsible practice requires thorough screening and informed consent.
The Clinical Safety Profile
Across dozens of clinical trials involving thousands of participants, psilocybin has demonstrated a favorable safety profile when administered in supervised therapeutic settings. Serious adverse events have been rare. There have been no reported deaths from psilocybin toxicity in any clinical trial, and its therapeutic index (the ratio between a therapeutic dose and a toxic dose) is among the widest of any pharmacologically active substance.
That said, “safe” doesn’t mean “without effects.” A psilocybin session is an intense experience, and temporary adverse effects are common.
Common Temporary Effects
The most frequently reported effects in clinical trials include headache (approximately 50% of participants), nausea (around 36%, usually mild and often resolving before the peak of the experience), emotional intensity and crying (reported by roughly 27%), fatigue (about 27%), and transient increases in blood pressure and heart rate during the acute phase.
These effects are temporary — typically resolving within 24 hours — and are managed within the clinical context. Nausea can be minimized through fasting protocols. Emotional intensity is often an integral part of the therapeutic process rather than a side effect. Blood pressure elevations are clinically monitored.
Transient Anxiety
One of the most important “side effects” to understand is transient anxiety during the session itself. Some participants experience periods of fear, confusion, or psychological distress — what older literature called a “difficult trip.” In clinical settings, these episodes are managed through facilitator support, grounding techniques, and the therapeutic relationship.
Critically, research suggests that when challenging moments are worked through rather than suppressed, they often lead to the most significant therapeutic breakthroughs. This is why facilitation skill matters so much, and why unsupervised use carries substantially higher psychological risk than supervised therapeutic use.
Who Should Not Take Psilocybin
Psilocybin is contraindicated in several populations. These aren’t relative cautions — they’re firm boundaries based on clinical evidence and safety data.
Psychotic spectrum disorders. Individuals with a personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I disorder with psychotic features should not take psilocybin. Psychedelics can trigger or worsen psychotic episodes in vulnerable individuals, and this risk is not mitigated by therapeutic supervision.
Lithium use. The combination of psilocybin and lithium has been associated with seizure risk and should be absolutely avoided.
MAOI use. Monoamine oxidase inhibitors interact with psilocybin’s serotonergic effects and create a risk of serotonin syndrome — a potentially life-threatening condition.
Uncontrolled cardiovascular conditions. The transient increases in blood pressure and heart rate during psilocybin sessions mean that individuals with uncontrolled hypertension, recent stroke or MI, or unstable cardiac conditions should be excluded or require specialized medical clearance.
The Screening Process
Comprehensive screening is a non-negotiable component of responsible psilocybin therapy. This includes a detailed psychiatric history (personal and family), a medical history and medication review, a cardiovascular assessment, a substance use history, a discussion of expectations and concerns, and informed consent covering both benefits and risks.
Screening is not a box-checking exercise — it’s a clinical evaluation that should be conducted by someone with the training to interpret the information and make sound decisions about appropriateness. Healing centers that skip or minimize screening should be avoided.
Supervised vs. Unsupervised Use
The safety data from clinical trials reflects supervised use — trained facilitators, controlled environments, screened participants, and medical oversight. The safety profile of unsupervised use is substantially different and harder to characterize.
In unsupervised settings, individuals may take unknown doses of unverified substances, lack access to support during challenging moments, combine psilocybin with other substances (including alcohol), and find themselves in environments that are not conducive to the experience.
Colorado’s regulated framework — with licensed healing centers, trained facilitators, and tested products — exists specifically to extend the safety profile demonstrated in clinical trials to real-world therapeutic access. This is a meaningful distinction from unregulated use.
Comparison to Other Treatments
Context helps. Psilocybin’s safety profile compares favorably to many widely prescribed psychiatric medications. SSRIs carry risks of sexual dysfunction, weight gain, emotional blunting, and discontinuation syndrome. Benzodiazepines carry risks of dependence, tolerance, and cognitive impairment. Lithium requires regular blood monitoring due to narrow therapeutic index. Antipsychotics carry risks of metabolic syndrome and tardive dyskinesia.
This is not to minimize psilocybin’s risks but to contextualize them within the broader landscape of psychiatric treatment. Every intervention involves trade-offs. What distinguishes psilocybin is the brevity of exposure (one or two sessions versus daily medication) and the absence of ongoing side effects between sessions.
Have questions about whether psilocybin therapy is appropriate for you? Get in touch or explore our FAQ.